The United States Food and Drug Administration says the shortage of Eli Lilly’s Zepbound and Mounjaro drugs has been resolved ...
The weight loss medication tirzepatide (Mounjaro and Zepbound) is no longer in shortage, according to the FDA. Access to ...
The decision will largely prevent compounding pharmacies from making and selling compounded versions of the drug in the next ...
Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 502.93% and ...
The FDA approved a new drug treatment for obstructive sleep apnea that improves the condition through weight loss. Sleep expert Dr. Wendy Troxel discusses the impact of the new development.
An international committee of experts will release an interim report in early 2025 outlining criteria for diagnosing ...
Among the many newcomers to the business of weight-loss drugs is Hims & Hers, an American e-pharmacy better known for hawking ...
Good news for the sleep apnea patients: the US has approved the first-ever drug treatment for them.According to Science Alert ...
Novo Nordisk has an opportunity to expand indications on its weight loss drugs. Check out on what could be next for NVO stock ...
The US FDA has approved the anti-diabetic drug Zepbound (Tirzepatide) for managing obstructive sleep apnea (OSA) in obese ...
A new evidence review says that coffee and tea consumption are linked to a lower risk of cancers of the mouth, throat, and ...